Lisata Therapeutics

LSTA

Biotechnology · Healthcare

Price

$1.55

+0.43 (+38.39%)

Market Cap

$14.1M

Exchange

NASDAQ Capital Market

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Based on the IPO prospectus (annual filing). This score will refine automatically once the company reports its first quarters.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Weak

Growth

Weak

Cash Flow

Weak

Stability

Good

Valuation

Data not available

Track this stock — start free trial

Share count rising — dilution

+135.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 3.7M (2021) → 8.7M (2025)

Winston Score History

The full picture

Lisata Therapeutics is a small clinical-stage biotechnology company focused on developing treatments for cancer and other serious diseases. Its lead product candidate, LSTA1 (formerly called certepetide), is designed to help chemotherapy drugs reach tumors more effectively by temporarily opening up blood vessels around the tumor. The company does not yet sell any approved products and primarily serves the oncology research space.

Lisata generates no meaningful product revenue today; its funding comes from capital raises and grants. The company is based in the United States and has a very small market capitalization, typical of early-stage biotech firms. Its potential competitive edge lies in its novel approach to improving drug delivery into solid tumors, but the key risk is significant: the company must demonstrate clinical efficacy in ongoing trials and secure additional funding to continue operations, with no guarantee that its therapies will receive regulatory approval.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-100.0% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+40.7% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$8M/ year

↓ Declining (-30% vs prior year)

>1,000% of revenue

259.8x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

18.7%ownership

Insiders own a meaningful stake in the company

Cash Runway

~12 months

$10M cash & investments

Quarterly Free Cash Flow

Adequate runway but may need to raise capital within 2 years

Revenue declining

Lisata Therapeutics's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

14.1%

Thin — 14.1% gross margin

Profit after running costs

Operating Margin

-10711.2%

Losing money on operations — -10711.2%

Return on the money invested

ROCE

-122.6%

Weak — -122.6% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-83.0%

Shrinking sales (-83.0% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-9398.2%

Burning cash (-9398.2%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.00

Conservative — low debt load (0.00)

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial